Zobrazeno 1 - 10
of 310
pro vyhledávání: '"Maria, Di Bartolomeo"'
Autor:
Monica Niger, Federico Nichetti, Lorenzo Fornaro, Chiara Pircher, Federica Morano, Federica Palermo, Lorenza Rimassa, Tiziana Pressiani, Rossana Berardi, Andrea Casadei Gardini, Elisa Sperti, Lisa Salvatore, Davide Melisi, Francesca Bergamo, Salvatore Siena, Stefania Mosconi, Raffaella Longarini, Giuseppina Arcangeli, Salvatore Corallo, Laura Delliponti, Stefano Tamberi, Elena Fea, Giovanni Brandi, Ilario Giovanni Rapposelli, Massimiliano Salati, Paolo Baili, Rosalba Miceli, Silva Ljevar, Ilaria Cavallo, Elisa Sottotetti, Antonia Martinetti, Michele Droz Dit Busset, Carlo Sposito, Maria Di Bartolomeo, Filippo Pietrantonio, Filippo de Braud, Vincenzo Mazzaferro
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Biliary tract cancers (BTCs) are rare and lethal cancers, with a 5-year survival inferior to 20%(1–3). The only potential curative treatment is surgical resection. However, despite complex surgical procedures that have a remarka
Externí odkaz:
https://doaj.org/article/90a788f11b2c4f01af1f8bfb71dabb48
Autor:
Ken Kato, Yuichiro Doki, Ian Chau, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Chih‐Hung Hsu, Antoine Adenis, Farid El Hajbi, Maria Di Bartolomeo, Maria Ignez Braghiroli, Eva Holtved, Tomoki Makino, Mariela Blum Murphy, Carlos Amaya‐Chanaga, Apurva Patel, Nan Hu, Yasuhiro Matsumura, Yuko Kitagawa, Jaffer Ajani
Publikováno v:
Cancer Medicine, Vol 13, Iss 9, Pp n/a-n/a (2024)
Abstract Background First‐line nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated significant overall survival (OS) benefit versus chemotherapy in previously untreated patients with advanced esophageal squamous cell carcino
Externí odkaz:
https://doaj.org/article/59c4231e83f941f6a4719927e06f1ef1
Autor:
Luca Guarrera, Mami Kurosaki, Silvio-Ken Garattini, Maurizio Gianni’, Gianpiero Fasola, Luca Rossit, Michele Prisciandaro, Maria Di Bartolomeo, Marco Bolis, Paola Rizzo, Claudia Nastasi, Marika Foglia, Adriana Zanetti, Gabriela Paroni, Mineko Terao, Enrico Garattini
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-20 (2023)
Abstract Background Gastric-cancer is a heterogeneous type of neoplastic disease and it lacks appropriate therapeutic options. There is an urgent need for the development of innovative pharmacological strategies, particularly in consideration of the
Externí odkaz:
https://doaj.org/article/afa7a8af41994fcf9273d86fa409c526
Autor:
Monica Niger, Federico Nichetti, Lorenzo Fornaro, Chiara Pircher, Federica Morano, Federica Palermo, Lorenza Rimassa, Tiziana Pressiani, Rossana Berardi, Andrea Casadei Gardini, Elisa Sperti, Lisa Salvatore, Davide Melisi, Francesca Bergamo, Salvatore Siena, Stefania Mosconi, Rafaella Longarini, Giuseppina Arcangeli, Salvatore Corallo, Laura Delliponti, Stefano Tamberi, Elena Fea, Giovanni Brandi, Ilario Giovanni Rapposelli, Massimiliano Salati, Paolo Baili, Rosalba Miceli, Silva Ljevar, Ilaria Cavallo, Elisa Sottotetti, Antonia Martinetti, Michele Droz Dit Busset, Carlo Sposito, Maria Di Bartolomeo, Filippo Pietrantonio, Filippo de Braud, Vincenzo Mazzaferro
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-2 (2024)
Externí odkaz:
https://doaj.org/article/c4ad272d3a0a4894a2606455a22c0d01
Autor:
Francesca Corti, Maria Pia Brizzi, Vito Amoroso, Dario Giuffrida, Francesco Panzuto, Davide Campana, Natalie Prinzi, Massimo Milione, Tommaso Cascella, Carlo Spreafico, Giovanni Randon, Simone Oldani, Rita Leporati, Giulia Scotto, Iolanda Pulice, Benedetta Lombardi Stocchetti, Luca Porcu, Jorgelina Coppa, Maria Di Bartolomeo, Filippo de Braud, Sara Pusceddu
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background Well-differentiated (WD) neuroendocrine tumors (NETs) are a group of rare neoplasms with limited therapeutic options. Cabozantinib is an inhibitor of multiple tyrosine kinases with a pivotal role in NET pathogenesis, including c-M
Externí odkaz:
https://doaj.org/article/b0d84bc55d694b8ea4f945306481f9f2
Autor:
Takayuki Yoshino, Maria Di Bartolomeo, Kanwal Raghav, Toshiki Masuishi, Fotios Loupakis, Hisato Kawakami, Kensei Yamaguchi, Tomohiro Nishina, Zev Wainberg, Elena Elez, Javier Rodriguez, Marwan Fakih, Fortunato Ciardiello, Kapil Saxena, Kojiro Kobayashi, Emarjola Bako, Yasuyuki Okuda, Gerold Meinhardt, Axel Grothey, Salvatore Siena, DESTINY-CRC01 investigators
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-13 (2023)
Abstract DESTINY-CRC01 (NCT03384940) was a multicenter, open-label, phase 2 trial assessing the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing metastatic colorectal cancer (mCRC) that progressed after ≥2 prio
Externí odkaz:
https://doaj.org/article/b78d3fdfa83149b6a91ce6f79897ff81
Autor:
Kohei Shitara, Kei Muro, Razvan Cristescu, Michael Nebozhyn, Andrey Loboda, Hyun Cheol Chung, Wasat Mansoor, Mustafa Ozguroglu, Mario Mandala, Maria Di Bartolomeo, Christian Caglevic, Julie Kobie, Min-Hee Ryu, Z Alexander Cao, Tomasz Olesinski, Eray Goekkurt, Raymond S McDermott, Zev A Wainberg, Chie-Schin Shih
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 6 (2023)
Background In the randomized, controlled, phase III KEYNOTE-061 trial, second-line pembrolizumab did not significantly prolong overall survival (OS) versus paclitaxel in patients with PD-L1-positive (combined positive score ≥1) advanced gastric/gas
Externí odkaz:
https://doaj.org/article/47cdd46fe09d4f619548677a08c6eb63
Autor:
Monica Niger, Federico Nichetti, Andrea Casadei‐Gardini, Federica Morano, Chiara Pircher, Elena Tamborini, Federica Perrone, Matteo Canale, Daniel B. Lipka, Andrea Vingiani, Luca Agnelli, Anna Dobberkau, Jennifer Hüllein, Felix Korell, Christoph E. Heilig, Sara Pusceddu, Francesca Corti, Michele Droz, Paola Ulivi, Michele Prisciandaro, Maria Antista, Marta Bini, Laura Cattaneo, Massimo Milione, Hanno Glimm, Bruno C. Köhler, Giancarlo Pruneri, Daniel Hübschmann, Stefan Fröhling, Vincenzo Mazzaferro, Filippo Pietrantonio, Maria Di Bartolomeo, Filippo deBraud
Publikováno v:
Molecular Oncology, Vol 16, Iss 14, Pp 2733-2746 (2022)
Biliary tract cancers (BTCs) have poor prognosis and limited therapeutic options. The impact of O6‐methylguanine‐DNA methyltransferase (MGMT) inactivation in advanced BTC patients is not established. We investigated the prevalence, prognostic, an
Externí odkaz:
https://doaj.org/article/3b4516fdda224755a9583e4ef6af9f00
Autor:
Stefano Cascinu, Maria Di Bartolomeo, Sara Lonardi, Giordano Beretta, Lorenzo Fornaro, Ferdinando De Vita
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
Gastric cancer (GC) is recognized as one of the most common deadly malignancies worldwide and about 40–50% of patients present at diagnosis with an unresectable disease due to a locally advanced or already metastatic condition. Recently, therapeuti
Externí odkaz:
https://doaj.org/article/631a15ab8ef749eb86d8e9524296b32f
Autor:
Michele Prisciandaro, Maria Antista, Alessandra Raimondi, Francesca Corti, Federica Morano, Giovanni Centonze, Giovanna Sabella, Alessandro Mangogna, Giovanni Randon, Filippo Pagani, Natalie Prinzi, Monica Niger, Salvatore Corallo, Erica Castiglioni di Caronno, Marco Massafra, Maria Di Bartolomeo, Filippo de Braud, Massimo Milione, Sara Pusceddu
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Neuroendocrine tumors (NETs) are classified based on morphology and are graded based on their proliferation rate as either well-differentiated low-grade (G1) to intermediate (G2–G3) or poorly differentiated high-grade neuroendocrine carcinomas (NEC
Externí odkaz:
https://doaj.org/article/7ae310bd6e49495dab2ddb83e0cd4b26